Endologix completed its merger with TriVascular Technologies in a $211m deal.

Endologix, which develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases, completed its merger with TriVascular Technologies, a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms, in a $211m deal. "The completion of the merger with TriVascular is a major milestone for both companies that further enhances our technology platforms and positions the combined business for robust growth with an accelerated path to profitability. Both teams have been working diligently preparing for the merger and we believe that we are well positioned to execute on our integration and commercial plans. In the near-term, our focus is on training the combined sales and clinical teams, introducing our comprehensive product portfolio to physicians and successfully capturing identified synergies," John McDermott, Endologix Chairman and CEO.